BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy

Andrew P. Barbour, Yue Hang Tang, Nicola Armour, Ken Dutton-Regester, Lutz Krause, Kelly A. Loffler, Duncan Lambie, Bryan H Burmeister, Janine Thomas, B. Mark Smithers, Nicholas K. Hayward

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)

Fingerprint

Dive into the research topics of 'BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences